Vertex Pharmaceuticals, Inc. (VRTX) Reports Q2 Loss of 85c, Beats by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts VRTX Hot Sheet
Price: $523.93 -2.1%
Revenue Growth %: +10.7%
Financial Fact:
Loss from operations: -18.73M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: +10.7%
Financial Fact:
Loss from operations: -18.73M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) reported Q2 EPS of ($0.85), $0.10 better than the analyst estimate of ($0.95). Revenue for the quarter came in at $114.42 million, versus $31.62 million reported last year.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vertex's povetacicept hits key endpoints in Phase 3 kidney disease trial
- Vertex Appoints Daniel Brennan to its Board of Directors
- Tompkins Financial (TMP) Tops Q3 EPS by 5c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
